Mereo Biopharma Group Plc ADR (MREO) Stock Price, Quote & News

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 33 3023 7300

Website: www.mereobiopharma.com

Address:

One Cavendish Place, 4th Floor, London, United Kingdom

poot_buttagina Feb. 4 at 3:44 AM

$MREO After feb. 10th delist notice watch for your entry.

1 · Reply

SaySomethingNice Feb. 3 at 2:27 PM

$GXAI $NBY $PDSB $MREO AMAZON WANTS $GXAI AND WILL FUND $$$ OPERATION.. 👍 - imo

0 · Reply

PennyGod1759 Feb. 3 at 2:04 PM

$MREO is today that day?

3 · Reply

actiontime77 Feb. 3 at 1:51 PM

$MREO weird how nobody cares about the delisting notice coming. Seems like nobody is concerned and looking past that

1 · Reply

Jassas2007 Feb. 3 at 7:50 AM

$MREO do u think price will go up this week👀

1 · Reply

Pharma3000 Feb. 2 at 7:21 PM

$MREO what you guys speak about delisting? When they present a Partner for Phase 3 of Alvelestat, this thing will fly back over 1.5$

2 · Reply

Brighams Feb. 2 at 6:38 PM

$MREO When will this be de-listed and de-registered? Or is an RS on the horizon?

1 · Reply

lisaparsons Feb. 2 at 12:25 PM

$MREO is rs imminent and nasdaq compliance. hard to tell as british company. took my loss and wondering whether to get back in, thanks team and blessings.

1 · Reply

octavia8 Feb. 2 at 4:57 AM

$MREO hopefully another green day

0 · Reply

Universaal Feb. 1 at 7:48 AM

$AUTL foreign trash 🗑️ like $MREO?

1 · Reply

Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Dec 29, 2025, 1:05 PM EST - 5 weeks ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

RARE

Dec 29, 2025, 8:31 AM EST - 5 weeks ago

Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Aug 19, 2025, 8:30 AM EDT - 6 months ago

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Aug 12, 2025, 7:35 AM EDT - 6 months ago

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Jul 10, 2025, 3:15 PM EDT - 7 months ago

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

May 13, 2025, 7:30 AM EDT - 9 months ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mar 26, 2025, 7:30 AM EDT - 11 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mar 5, 2025, 7:30 AM EST - 11 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 7, 2025, 7:30 AM EST - 1 year ago

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 1:36 PM EST - 1 year ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Nov 14, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 12, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Sep 12, 2024, 5:35 PM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:50 AM EDT - 1 year ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

May 30, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 15, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 5:34 PM EDT - 2 years ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS TAK WVE

Mar 5, 2024, 7:30 AM EST - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Jan 8, 2024, 7:00 AM EST - 2 years ago

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Oct 23, 2023, 4:01 PM EDT - 2 years ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Sep 7, 2023, 7:30 AM EDT - 2 years ago

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

May 31, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 23, 2023, 1:43 PM EDT - 2 years ago

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

May 8, 2023, 12:46 PM EDT - 2 years ago

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 5, 2023, 4:06 PM EDT - 2 years ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Mar 28, 2023, 4:30 PM EDT - 3 years ago

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mar 21, 2023, 6:30 AM EDT - 3 years ago

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Feb 8, 2023, 7:00 AM EST - 3 years ago

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Nov 2, 2022, 4:01 PM EDT - 3 years ago

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Oct 28, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Oct 24, 2022, 4:30 PM EDT - 3 years ago

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Oct 21, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Oct 18, 2022, 11:58 AM EDT - 3 years ago

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Oct 18, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Oct 3, 2022, 5:00 PM EDT - 3 years ago

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

poot_buttagina Feb. 4 at 3:44 AM

$MREO After feb. 10th delist notice watch for your entry.

1 · Reply

SaySomethingNice Feb. 3 at 2:27 PM

$GXAI $NBY $PDSB $MREO AMAZON WANTS $GXAI AND WILL FUND $$$ OPERATION.. 👍 - imo

0 · Reply

PennyGod1759 Feb. 3 at 2:04 PM

$MREO is today that day?

3 · Reply

actiontime77 Feb. 3 at 1:51 PM

$MREO weird how nobody cares about the delisting notice coming. Seems like nobody is concerned and looking past that

1 · Reply

Jassas2007 Feb. 3 at 7:50 AM

$MREO do u think price will go up this week👀

1 · Reply

Pharma3000 Feb. 2 at 7:21 PM

$MREO what you guys speak about delisting? When they present a Partner for Phase 3 of Alvelestat, this thing will fly back over 1.5$

2 · Reply

Brighams Feb. 2 at 6:38 PM

$MREO When will this be de-listed and de-registered? Or is an RS on the horizon?

1 · Reply

lisaparsons Feb. 2 at 12:25 PM

$MREO is rs imminent and nasdaq compliance. hard to tell as british company. took my loss and wondering whether to get back in, thanks team and blessings.

1 · Reply

octavia8 Feb. 2 at 4:57 AM

$MREO hopefully another green day

0 · Reply

Universaal Feb. 1 at 7:48 AM

$AUTL foreign trash 🗑️ like $MREO?

1 · Reply

Jassas2007 Jan. 31 at 5:06 PM

$MREO

0 · Reply

octavia8 Jan. 30 at 8:54 PM

$MREO hope this breaks 0.50 on monday..

0 · Reply

octavia8 Jan. 30 at 7:14 PM

$MREO maybe they want it back over a dollar before delisting announcement can happen

0 · Reply

octavia8 Jan. 30 at 7:05 PM

$MREO

0 · Reply

actiontime77 Jan. 30 at 3:12 PM

$MREO love this stock just waiting for everyone to get out that doesn't believe. Then I'll add

0 · Reply

SebNo1234 Jan. 30 at 3:05 PM

$MREO I hope of good news soon 🤞🤞🍀🍀🚀🚀

1 · Reply

janithasandama567 Jan. 30 at 2:42 PM

$MREO start again to climb hopefully we can see +1 in February

1 · Reply

Dou_said_it Jan. 30 at 10:43 AM

$MREO all th market is RED and RED… - Gold : RED - Crypto: RED - Biotech : RED So HOLD , green soon

0 · Reply

Marc1283 Jan. 30 at 12:36 AM

$MREO

0 · Reply

poot_buttagina Jan. 29 at 7:25 PM

$MREO If you are looking to enter i suggest waiting. 9 more trading days til delist notice which will drop the stock 25% to 50% from wherever it is. That's your chance to buy as it will certainly be a temporary bottom. Within a week after delist notice a 180 day extension will be announced to help push the price back up. Glta

1 · Reply

GreyMan76 Jan. 29 at 6:07 PM

$MREO Bottomed?

0 · Reply

ThunderCoopersmith Jan. 29 at 5:56 PM

$MREO what happened here in December?

1 · Reply

Market Cap	530.17M
Revenue (ttm)	10.00M
Net Income (ttm)	-29.47M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	28,075
Avg Vol	812,584
Day's Range	N/A - N/A
Shares Out	140.26M
Stochastic %K	30%
Beta	0.88
Analysts	Strong Sell
Price Target	$6.80